Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research
Pharmaceutics · 03.02.2024 · 16 (2) · 221
DOI: 10.3390/pharmaceutics16020221 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pharmaceutics, online erschienen am 03.02.2024. Verfasst von Youngbo Choi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Safety Engineering, Chungbuk National University, Cheongju 28644, Chungbuk, Republic of Korea. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 82 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Research Foundation of Korea, Korea Technology and Information Promotion Agency for SMEs, Ministry of SMEs and Startups.
Abstract (Originalsprache)
Antibody–drug conjugate (ADC) therapy, an advanced therapeutic technology comprising antibodies, chemical linkers, and cytotoxic payloads, addresses the limitations of traditional chemotherapy. This study explores key elements of ADC therapy, focusing on antibody development, linker design, and cytotoxic payload delivery. The global rise in cancer incidence has driven increased investment in anticancer agents, resulting in significant growth in the ADC therapy market. Over the past two decades, notable progress has been made, with approvals for 14 ADC treatments targeting various cancers by 2022. Diverse ADC therapies for hematologic malignancies and solid tumors have emerged, with numerous candidates currently undergoing clinical trials. Recent years have seen a noteworthy increase in ADC therapy clinical trials, marked by the initiation of numerous new therapies in 2022. Research and development, coupled with patent applications, have intensified, notably from major companies like Pfizer Inc. (New York, NY, USA), AbbVie Pharmaceuticals Inc. (USA), Regeneron Pharmaceuticals Inc. (Tarrytown, NY, USA), and Seagen Inc. (Bothell, WA, USA). While ADC therapy holds great promise in anticancer treatment, challenges persist, including premature payload release and immune-related side effects. Ongoing research and innovation are crucial for advancing ADC therapy. Future developments may include novel conjugation methods, stable linker designs, efficient payload delivery technologies, and integration with nanotechnology, driving the evolution of ADC therapy in anticancer treatment.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Safety Engineering, Chungbuk National University, Cheongju 28644, Chungbuk, Republic of Korea.
- Department of BigData, Chungbuk National University, Cheongju 28644, Chungbuk, Republic of Korea.
- Department of Biotechnology, CHA University, Pocheon 11160, Gyeonggi, Republic of Korea.
ORCID-Profile: Youbeen Choi
Förderung
- National Research Foundation of Korea
- Korea Technology and Information Promotion Agency for SMEs
- Ministry of SMEs and Startups
Zitieren
APA
Choi, Y., Choi, Y., & Hong, S. (2024). Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research. Pharmaceutics, 16(2), 221. https://doi.org/10.3390/pharmaceutics16020221
Vancouver
Choi Y, Choi Y, Hong S. Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research. Pharmaceutics. 2024;16(2):221. doi:10.3390/pharmaceutics16020221
BibTeX
@article{Choi2024,
author = {Choi, Youngbo and Choi, Youbeen and Hong, Surin},
title = {Recent Technological and Intellectual Property Trends in Antibody–Drug Conjugate Research},
journal = {Pharmaceutics},
year = {2024},
volume = {16},
number = {2},
pages = {221},
doi = {10.3390/pharmaceutics16020221}
}
EUVIMED